Personal information

Other IDs

Scopus Author ID: 35797920500
Scopus Author ID: 57194022808

Countries

Canada

Activities

Collapse all

Education and qualifications (5)

Dana Farber Cancer Institute: Boston, MA, US

2019-01-01 to present | Fellow (Radiation Oncology)
Education
Source: Self-asserted source
Andrew Bang

Princess Margaret Cancer Centre: Toronto, Ontario, CA

2017-07-01 to 2018-12-31 | Fellow (Radiation Oncology)
Education
Source: Self-asserted source
Andrew Bang

University of Ottawa Faculty of Medicine: Ottawa, ON, CA

2012-07-01 to 2017-06-30 | FRCPC (Radiation Oncology)
Education
Source: Self-asserted source
Andrew Bang

McMaster University Michael G DeGroote School of Medicine: Hamilton, ON, CA

2009-09-01 to 2012-06-30 | MD (Medicine)
Education
Source: Self-asserted source
Andrew Bang

York University: Toronto, ON, CA

2006-09-01 to 2009-05-01 | BSc (Biology)
Education
Source: Self-asserted source
Andrew Bang

Works (11)

Five-Fraction High-Conformal Ultrahypofractionated Radiotherapy for Primary Tumors in Metastatic Breast Cancer

Journal of Breast Cancer
2024 | Journal article
DOI: 10.4048/jbc.2024.0004
Contributors: Jeongshim Lee; Jee Hung Kim; Mitchell Liu; Andrew Bang; Robert Olson; Jee Suk Chang
Source: check_circle
Crossref

Predictors of Quality of Life Decline in Patients with Oligometastases treated with Stereotactic Ablative Radiotherapy: Analysis of the Population-Based SABR-5 Phase II Trial

Clinical Oncology
2024-01 | Journal article
DOI: 10.1016/j.clon.2024.01.007
Contributors: E.M. Cruz-Lim; B. Mou; W. Jiang; M. Liu; A. Bergman; D. Schellenberg; A. Alexander; T. Berrang; A. Bang; N. Chng et al.
Source: check_circle
Crossref

The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors

International Journal of Radiation Oncology Biology Physics
2019 | Journal article
DOI: 10.1016/j.ijrobp.2018.09.010
EID:

2-s2.0-85058405921
Contributors: Pike, L.R.G.; Bang, A.; Mahal, B.A.; Taylor, A.; Krishnan, M.; Spektor, A.; Cagney, D.N.; Aizer, A.A.; Alexander, B.M.; Rahma, O. et al.
Source: Self-asserted source
Andrew Bang via Scopus - Elsevier

Radiation dose mapping and anastomotic complications after trimodality therapy for esophageal cancers

Clinical and Translational Radiation Oncology
2019-02 | Journal article
DOI: 10.1016/j.ctro.2018.12.005
Contributors: Andrew Bang; Joel A. Broomfield; Jessica Chan; Najlaa Alyamani; Agnes Crnic; Sebastien Gilbert; Jason R. Pantarotto
Source: check_circle
Crossref

Prophylactic Cranial Irradiation in Extensive Stage Small Cell Lung Cancer: Outcomes at a Comprehensive Cancer Centre

International Journal of Radiation Oncology Biology Physics
2018 | Journal article
DOI: 10.1016/j.ijrobp.2018.04.058
EID:

2-s2.0-85048803971
Contributors: Bang, A.; Kendal, W.S.; Laurie, S.A.; Cook, G.; MacRae, R.M.
Source: Self-asserted source
Andrew Bang via Scopus - Elsevier

Immunotherapy and radiotherapy for metastatic cancers.

Annals of palliative medicine
2018-08 | Journal article
DOI: 10.21037/apm.2018.07.10
PMID: 30180743
Contributors: Bang A; Schoenfeld JD
Source: Self-asserted source
Andrew Bang via Europe PubMed Central

Radiation and PD-1 inhibition: Favorable outcomes after brain-directed radiation

Radiotherapy and Oncology
2017-07 | Journal article
DOI: 10.1016/j.radonc.2017.06.006
Contributors: Luke R.G. Pike; Andrew Bang; Patrick Ott; Tracy Balboni; Allison Taylor; Paul Catalano; Bhupendra Rawal; Alexander Spektor; Monica Krishnan; Daniel Cagney et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Multicenter Evaluation of the Tolerability of Combined Treatment With PD-1 and CTLA-4 Immune Checkpoint Inhibitors and Palliative Radiation Therapy

International Journal of Radiation Oncology*Biology*Physics
2017-06 | Journal article
DOI: 10.1016/j.ijrobp.2017.02.003
Contributors: Andrew Bang; Tyler J. Wilhite; Luke R.G. Pike; Daniel N. Cagney; Ayal A. Aizer; Allison Taylor; Alexander Spektor; Monica Krishnan; Patrick A. Ott; Tracy A. Balboni et al.
Source: check_circle
Crossref
grade
Preferred source (of 2)‎

Absence of equilibrative nucleoside transporter 1 in ENT1 knockout mice leads to altered nucleoside levels following hypoxic challenge

Life Sciences
2011 | Journal article
DOI: 10.1016/j.lfs.2011.08.007
EID:

2-s2.0-80053565855
Contributors: Rose, J.B.; Naydenova, Z.; Bang, A.; Ramadan, A.; Klawitter, J.; Schram, K.; Sweeney, G.; Grenz, A.; Eltzschig, H.; Hammond, J. et al.
Source: Self-asserted source
Andrew Bang via Scopus - Elsevier

Equilibrative nucleoside transporter 1 plays an essential role in cardioprotection

American Journal of Physiology - Heart and Circulatory Physiology
2010 | Journal article
DOI: 10.1152/ajpheart.00711.2009
EID:

2-s2.0-77749254666
Contributors: Rose, J.B.; Naydenova, Z.; Bang, A.; Eguchi, M.; Sweeney, G.; Choi, D.-S.; Hammond, J.R.; Coe, I.R.
Source: Self-asserted source
Andrew Bang via Scopus - Elsevier

Nucleoside transporter expression profiles in human cardiac tissue show striking individual variability with overall predominance of hENT1

European Journal of Pharmaceutical Sciences
2010 | Journal article
DOI: 10.1016/j.ejps.2010.09.013
EID:

2-s2.0-78349313091
Contributors: Marvi, M.; Rose, J.B.; Bang, A.; Moon, B.C.; Pozeg, Z.; Ibrahim, M.; Peniston, C.; Coe, I.R.
Source: Self-asserted source
Andrew Bang via Scopus - Elsevier
How many people are using ORCID?